© Reuters. A compagny logo is seen at a Pfizer office in Puurs, Belgium, December 2, 2022. REUTERS/Johanna Geron/File Photo
(Reuters) -Pfizer and German partner BioNTech (NASDAQ:) said on Thursday that their vaccine to prevent flu and COVID-19 generated a strong immune response against strains of the viruses in an early- to mid-stage trial.
The companies said they plan to start a late-stage trial in the coming months.
“This vaccine has the potential to lessen the impact of two respiratory diseases with a single injection and may simplify immunization practices,” Annaliesa Anderson, Pfizer (NYSE:)’s head of vaccine research and development, said in a statement.
In the trial, the vaccine candidates were compared to a licensed influenza vaccine and the companies’ updated COVID-19 vaccine given at the same visit.
The data from the trial showed that the flu-COVID vaccine demonstrated robust immune responses to influenza A, influenza B and SARS-CoV-2 strains, the companies said.
Read the full article here
